Clinical Study

Effect of Cerivastatin on Urinary Albumin Excretion and Plasma Endothelin-1 Concentrations in Type 2 Diabetes Patients with Microalbuminuria and Dyslipidemia
Tsukasa Nakamura^a, Chifuyu Ushiyama^a, Kaoru Hirokawa^a, Shiwori Osada^b, Noriaki Shimada^c, Hikaru Koide<sup>c

a</sup>Department of Medicine, Misato Junshin Hospital, Saitama,
^bDepartment of Medicine, National Rehabilitation Center, Saitama, and
^cDepartment of Medicine, Koto Hospital, Tokyo, Japan

Address of Corresponding Author

Am J Nephrol 2001;21:449-454 (DOI: 10.1159/000046648)

  Key Words

• HMG-CoA reductase inhibitor
• Diabetes
• Microalbuminuria
• Endothelial cell
• Endothelin

  Abstract

Background/Aims: To determine whether cerivastatin, a newly developed novel synthetic potent statin, exerts a renoprotective effect, we assessed urinary albumin excretion (UAE) and plasma and urinary endothelin (ET)-1 concentrations in normotensive microalbuminuric type 2 diabetes patients with dyslipidemia. Methods: Sixty normotensive type 2 diabetic patients (38 men and 22 women; mean age 56.5 years) with microalbuminuria (20-200 µg/min) and dyslipidemia (total cholesterol >200 mg/dl, LDL cholesterol >160 mg/dl, HDL cholesterol <35 mg/dl, and triglyceride >150 mg/dl) were enrolled in a double-blind study for 6 months, receiving either cerivastatin (0.15 mg/day) or placebo. Plasma and urinary ET-1 concentrations were measured by radioimmunoassay. Results: Cerivastatin did not affect serum creatinine and HbA_1c levels, and reduced systolic blood pressure slightly, but not significantly. Plasma levels of total cholesterol and LDL cholesterol were significantly reduced (p < 0.01), and plasma triglyceride levels were also reduced significantly (p < 0.05) after 6 months of cerivastatin treatment. A concomitant significant decrease in UAE (p < 0.01), and urinary and plasma ET-1 concentrations (p < 0.01) were found during this period. Conclusion: The use of cerivastatin is associated with decreased microalbuminuria and plasma and urinary ET-1 levels in microalbuminuric patients with type 2 diabetic mellitus and speculate that this may represent an amelioration of renal injury.

Copyright © 2001 S. Karger AG, Basel

  Author Contacts

Hikaru Koide, MD
Department of Medicine, Koto Hospital
6-8-5 Ojima, Koto-ku
Tokyo 136-0072 (Japan)
Tel. +81 3 3685 2166, Fax +81 3 3683 1347, E-Mail hkoide@koto-hospital.or.jp

  Article Information

Received: Received: May 21, 2001
Accepted: August 7, 2001
Number of Print Pages : 6
Number of Figures : 2, Number of Tables : 2, Number of References : 31